Catalyst Dossier · compiled by Celia 🧫

ASTRAZENECA PLC (AZNCF)

Biotechnology · market cap $290.6B · as of 2026-06-23

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-06-30 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

AstraZeneca PLC (AZNCF) is a large-cap biopharmaceutical company with approximately 94,300 employees and a market capitalization of roughly $290.6 billion. The company operates a broad pipeline spanning oncology, cardiovascular, respiratory, metabolic disease, and immunology, with multiple Phase 2 and Phase 3 catalysts expected between mid-2026 and early 2027. Notably, the data provided lists several off-patent generics (simvastatin, metformin, paroxetine, rosuvastatin, esomeprazole, anastrozole) alongside proprietary assets (osimertinib, olaparib, dapagliflozin, durvalumab, capivasertib), suggesting the pipeline data reflects a mix of legacy and active development programs.

The catalyst path

2026-06-30 (est.)Phase 2 · Oleclumabimp 7/10
2026-07-01 (est.)Phase 2 · Durvalumabimp 7/10
2026-07-06 (est.)Phase 3 · Taxaneimp 9/10
2026-07-08 (est.)Phase 2 · AZD6234imp 7/10
2026-07-31 (est.)Phase 2 · Zibotentan/Dapagliflozinimp 7/10
2026-08-20 (est.)Phase 2 · AZD7798imp 7/10
2026-12-08 (est.)Phase 2 · Carboplatinimp 7/10
2027-01-04 (est.)Phase 3 · AZD0780imp 9/10

Pipeline

Asset	Phase	Indication
CIN-107 2 mg dosing	Phase 2	Primary Aldosteronism
Simvastatin	Phase 3	Hypercholesterolemia
MEDI4736 + Tremelimumab	Phase 2	Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck
Paroxetine	Phase 3	Generalized Anxiety Disorder
abiraterone acetate	Phase 3	Metastatic Castration-resistant Prostate Cancer
Capivasertib	Phase 3	Triple Negative Breast Neoplasms
Metformin IR	Phase 3	Diabetes Mellitus, Type 2
Formoterol (OT)	Phase 3	Chronic Obstructive Pulmonary Disease
Tomudex	Phase 2	Inoperable or Recurrent Rectal Cancer
fostamatinib	Phase 3	Rheumatoid Arthritis
AZD0837	Phase 2	Persistent or Permanent Non-valvular Atrial Fibrillation
fluticasone	Phase 3	Asthma
Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)	Phase 3	Chronic Obstructive Pulmonary Disease
Anastrozole	Phase 3	Breast Neoplasms
Roflumilast	Phase 3	Asthma
AZD7798	Phase 2	Moderate to Severe Crohn's Disease
metformin	Phase 3	Type 2 Diabetes Mellitus
SEROQUEL (quetiapine fumarate) Tablets	Phase 3	Bipolar Disorder
Taxane	Phase 3	Breast Cancer; HER2-positive; Metastatic
Rosuvastatin	Phase 3	Aortic Stenosis

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by Celia. The catalyst path & pipeline above are free.

See Pro

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by Celia. Not financial advice.